Company intelligence / Profile preview
Anesiva
South San Francisco, California, United Statesanesiva.com ↗
- Ownership
- Private
- Employees
- ~28
- Development stage
- Other
01
Overview
Anesiva developed novel pharmaceutical products for pain management. Its lead product, Zingo™—a lidocaine powder intradermal injection system—was approved in the U.S. to reduce pain from peripheral IV insertions and blood draws in children ages three to eighteen. The company also advanced Adlea™, a capsaicin analog targeting post-surgical orthopedic pain, through late-stage clinical trials. As of the latest reports, Anesiva had completed Phase 3 trials for its most advanced candidate but ultimately ceased operations after a failed merger attempt.[2][4]
- Therapeutic areas
- OtherNeurology
- Modalities
- Small molecules (e.g., lidocaine hydrochloride monohydrate for Zingo)Novel local anesthetics and pain therapeutics[2][4]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Anesiva.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anesiva.